

Michael Krainer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5751293/michael-krainer-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

1,458
citations

11
h-index

31
g-index

31
ext. papers

1,764
ext. citations

5.4
avg, IF

3.5
L-index

#	Paper	IF	Citations
27	The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2021 ,	9.9	3
26	Impact of frailty on the management of patients with gynecological cancer aged 80 years and older. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 557-563	2.5	2
25	Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. <i>Translational Research</i> , 2021 , 230, 21-33	11	2
24	Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	7
23	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020 , 5, e000880	6	1
22	Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 309-315	6.2	12
21	Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020 , 125, 153-163	7.5	3
20	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020 , 78, 822-830	10.2	45
19	Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. <i>OncImmunology</i> , 2019 , 8, e1644109	7.2	17
18	Synthetic lethality guiding selection of drug combinations in ovarian cancer. <i>PLoS ONE</i> , 2019 , 14, e0210859	3.7	11
17	Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2018 , 97, 41-48	7.5	8
16	LUBAC and ABIN-1 Modulate TRAIL-Based NF- κ B Induction in Human Embryonic Kidney 293 Cells. <i>BioResearch Open Access</i> , 2018 , 7, 81-89	2.4	2
15	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018 , 1, 467-475	6.7	18
14	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018 , 9, 812-823	3.3	21
13	Analysis of hematological parameters as prognostic markers for toxicity and survival of Radium treatment. <i>Oncotarget</i> , 2018 , 9, 16197-16204	3.3	5
12	Synthetic lethal combinations of low-toxicity drugs for breast cancer identified by genetic screens in yeast. <i>Oncotarget</i> , 2018 , 9, 36379-36391	3.3	3
11	Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2017 , 193, 1056-1065	4.3	16

10	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017 , 2, e000166	6	3
9	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3005-13	2.2	163
8	32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016. <i>EJNMMI Research</i> , 2016 , 6, 32	3.6	
7	HIF1 α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2015 , 13, 556-64	6.6	63
6	Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. <i>International Journal of Cancer</i> , 2015 , 137, 1330-40	7.5	35
5	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 139-139	2.2	21
4	The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. <i>PLoS ONE</i> , 2015 , 10, e0133838	3.7	6
3	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 700-12	21.7	982
2	Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study. <i>PLoS ONE</i> , 2014 , 9, e95310	3.7	3
1	A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 2141-5; discussion 2145	2.5	6